Nucryst Pharmaceuticals $ 4,754 $ 6,686 $ 9,962 $ 12,817
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(Loss) income from continuing
operations
Nucryst Pharmaceuticals $ (1,781) $ (3,322) $ (4,019) $ (5,501)
Other (including corporate
costs) (106) 6,197 5,359 10,275
-------------------------------------------------------------------------
(Loss) income from continuing
operations $ (1,887) $ 2,875 $ 1,340 $ 4,774
-------------------------------------------------------------------------
-------------------------------------------------------------------------
June December
Consolidated Balance Sheets 30, 2008 31, 2007
-----------------------------------------------------
Cash and cash equivalents $ 40,121 $ 30,993
Current assets 48,350 51,561
Other assets 24,324 31,826
Current liabilities 7,992 8,461
Shareholders' equity 47,330 56,371
| SOURCE Westaim Corporation Copyright©2008 PR Newswire. All rights reserved |